| O 基金经理 : 金晟哲 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 会晟哲 | 累计任职时间：8年又289天 任职起始日期：2016-10-24 现任基金公司：博时基金管理有限公司 现任基金资产 - 在管基金最佳 总规模 任期回报 49.16 乙元 88.78% | | 基金经理简介:金晟哲先生:中国国籍,硕士。2012年从北京大学硕士研究生毕业后加入博时基 金管理有限公司。历任研究员、高级研究员、资深研究员、博时睿利定增灵活配置混合型证 券投资基金(2017年2月28日-2017年12月1日)、博时睿益定增灵活配置混合型证券投资基金 (2017年2月28日-2018年2月22日)、博时睿益事件驱动灵活配置混合型证券投资基金(LOF) (2018年2月23日-2018年8月13日)、博时睿丰灵活配置定期开放混合型证券投资基金(2017年 3月22日-2018年12月8日)的基金经理、研究部副总经理、博时价值增长证券投资基金(2017年 11月13日-2021年7月12日)、博时睿利事件驱动灵活配置混合型证券投资基 ...

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. plans to lease out part of its idle assets located at 109 Xuefu Road, Harbin, to enhance asset utilization and generate stable rental income, which is expected to positively impact the company's financial status [5][14]. Group 1: Board Meeting and Decision - The company's board of directors held its sixteenth meeting on August 4, 2025, where it unanimously approved the proposal to lease out idle assets [1][4]. - The decision to lease was based on a previous resolution from the thirteenth board meeting on April 25, 2025, aimed at revitalizing idle assets and improving asset efficiency [2][6]. Group 2: Asset Details - The assets to be leased include 10 buildings with a total area of 22,671.39 square meters, part of the Harbin Pharmaceutical Group's manufacturing facility [9]. - The leased properties are free from any ownership disputes or legal encumbrances, ensuring a clear title for the leasing process [9]. Group 3: Leasing Terms - The lease term is set for 10 years, including a rent-free period of 60 to 180 days for renovations, with rental fees to be borne by the lessee [10][11]. - Rental prices will be based on a market assessment report, with specific annual increases outlined for the subsequent years [11][12]. Group 4: Impact on Company - The leasing of idle assets is expected to improve asset utilization and provide a stable income stream, contributing positively to the company's future financial health [14]. - The leasing process will follow a market-oriented approach, ensuring fairness and transparency in the selection of tenants [8].

Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]

证券代码：600664 证券简称：哈药股份 编号：临 2025-029 哈药集团股份有限公司 关于公司分公司挂牌出租部分闲置资产的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容：哈药集团股份有限公司（以下简称"公司"）拟通 过挂牌出租的方式对位于哈尔滨市南岗区学府路 109 号的分公司哈药集 团制药总厂（以下简称"哈药总厂"）部分闲置资产进行盘活。 根据《上海证券交易所股票上市规则》《上市公司重大资产重组管 理办法》，上述事项无须提交股东大会审议，也不构成关联交易和重大 资产重组。 相关风险提示：受政策、市场环境变化等因素影响，本次闲置资产 盘活方案在交易对方、交易价格及实施进度等方面仍存在不确定性，敬 请投资者理性决策，注意防范投资风险。 一、交易概述 2025 年 4 月 25 日，公司第十届董事会第十三次会议审议通过了《关 于公司分公司哈药集团制药总厂资产处置的议案》，为了落实董事会决 议，盘活存量闲置资产，提高资产使用效率，按照哈药总厂学府路厂区 整体规划设计，公司拟通过挂牌出租的方式 ...

哈药集团股份有限公司 十届十六次董事会决议公告 证券代码：600664 证券简称：哈药股份 编号：临 2025-028 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露 的《哈药集团股份有限公司关于公司分公司挂牌出租部分闲置资产的公告》 1 （公告编号：2025-029）。 特此公告。 哈药集团股份有限公司董事会 二〇二五年八月五日 2 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第十届董事会第十六次 会议以书面方式发出通知，于 2025 年 8 月 4 日以现场结合通讯形式召开。 会议应参加董事 9 人，实际参加董事 9 人，其中公司董事孙峙峰先生及刘 墨先生因工作原因分别授权委托董事胡晓萍女士、尹世炜先生出席会议并 行使表决权。会议召开符合《中华人民共和国公司法》和《公司章程》的 有关规定，会议审议通过了《关于公司分公司挂牌出租部分闲置资产的议 案》（同意 9 票，反对 0 票，弃权 0 票）。 根据第十届董事会第十三次会议决议，公司积极推进分公司哈药集 ...

2024年1至12月份，哈药股份的营业收入构成为：批发医疗客户占比36.87%，医药工业-保健品占比 16.14%，化学制剂占比15.87%，批发商业客户占比13.99%，医药商业-零售占比10.46%。 （文章来源：每日经济新闻） 哈药股份（SH 600664，收盘价：4.03元）8月4日晚间发布公告称，公司第十届第十六次董事会会议于 2025年8月4日以现场结合通讯形式召开。会议审议了《关于公司分公司挂牌出租部分闲置资产的议案》 等文件。 ...

哈药股份8月4日公告，公司拟通过挂牌出租的方式对位于哈尔滨市南岗区学府路109号的分公司哈药集 团制药总厂部分闲置资产进行盘活。该部分资产包括10栋房产，总面积为22,671.39平方米。租赁价格不 低于评估价格，租赁期为10年。本次交易不构成关联交易和重大资产重组，无需提交股东大会审议。但 受市场环境等因素影响，交易对方、交易价格及实施进度等方面仍存在不确定性。 ...

金融界消息 截至2025年7月29日收盘，哈药股份（600664）报收于4.05元，上涨1.76%，换手率3.06%， 成交量77.00万手，成交金额3.09亿元。 资金流向方面，今日主力资金净流入1184.05万元，占比成交额3.83%。其中，超大单净流入2250.76万 元、占成交额7.28%，大单净流出1066.71万元、占成交额3.45%，中单净流出流出1314.85万元、占成交 额4.26%，小单净流入130.80万元、占成交额0.42%。 通过天眼查大数据分析，哈药集团股份有限公司共对外投资了30家企业，参与招投标项目3212次，知识 产权方面有商标信息2条，专利信息67条，此外企业还拥有行政许可19个。 来源：金融界 哈药股份最新一期业绩显示，截至2025一季报，公司营业总收入41.74亿元、同比增长0.78%，归属净利 润2.13亿元，同比增长20.48%，扣非净利润2.04亿元，同比增长28.06%，流动比率1.424、速动比率 1.177、资产负债率55.24%。 天眼查商业履历信息显示，哈药集团股份有限公司，成立于1991年，位于哈尔滨市，是一家以从事医药 制造业为主的企业。企业注册资本 ...

Core Viewpoint - 哈药股份 is focusing on enhancing its product offerings and operational efficiency to drive growth and maintain competitiveness in the pharmaceutical industry Group 1: Business Operations and Strategy - The company held an analyst meeting on July 24, 2023, with participation from various financial institutions, discussing its business strategies and product lines [1] - The company plans to improve sales of its key nutritional supplements, with year-on-year sales growth of 72.84% for compound calcium gluconate oral solution and 51.30% for zinc gluconate oral solution [1] - The company is adjusting its marketing strategies for GNC China, focusing on e-commerce channel development, cost management, and brand value enhancement to ensure compliance and high-quality growth [1] Group 2: Research and Development - From 2024 to 2028, the company will focus its R&D efforts on five major therapeutic areas: cardiovascular, digestive metabolism, respiratory, anti-infection, and anti-tumor, along with elderly and pediatric medications [2] - The company aims to transition its R&D strategy from a focus on generic drugs to a combination of generics and innovative products, enhancing its product line [2] - The company has already received approval for a generic drug, lactulose oral solution, and is working on several other products expected to be approved in the near future [2] Group 3: Asset Management and Operational Improvement - The company is working on integrating raw material and formulation processes to control product costs and improve competitiveness [3] - The company is actively pursuing the revitalization of idle assets at its subsidiary, 哈药集团制药总厂, and has approved plans for phased asset disposal [3] Group 4: Long-term Vision and Mission - The company's long-term strategy is to provide quality medications for public health and to become a benchmark in the Chinese pharmaceutical industry [4] - The company aims for high-quality and sustainable development, supported by a complete product and talent pipeline, brand strategy, and marketing innovation [4]

证券代码：600664 证券简称：哈药股份 编号：临 2025-027 哈药集团股份有限公司 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 哈药集团股份有限公司（以下简称"公司"）控股股东哈药集团 有限公司（以下简称"哈药集团"）持有公司股份 1,173,237,023 股，占 本公司总股本的 46.58%；本次质押完成后，哈药集团累计质押股份 一、公司股份质押 公司于近日收到哈药集团的告知函，获悉哈药集团所持有的 90,264,182 股公司股份办理了质押登记手续，具体事项如下： 占其 占公 是否 是否为限 质押 | | | | 是否 | | | | | 所持 | | 司总 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 为控 | 本次质押 | | 售股（如 | | 质押起 | | 质押 | | | | | | 到 | | | 融资 | | | | | | | | | | | | | | | 补充 | | | | 质权人 | 股份 | | 股 ...